StockWatch
·

Research Reports

04 Nov 2026
ZYDUSLIFEZydus Lifesciences Ltd

Zydus Q2 FY27: PAT falls 25% YoY to ₹925 Cr, below Street, as M&A-led revenue surges 29%

pharmaceuticals · margin compression · acquisition integration

ResultsQ2 FY273 minPharma & Healthcare
03 Nov 2026
NOVARTINDNOVARTIS INDIA LTD.

Evonile Pharma (ex-Novartis India) swings to ₹77.5 Cr standalone loss on customer exit

pharmaceuticals · change of control · customer termination

ResultsQ2 FY273 minPharma & Healthcare
GLAXOGLAXOSMITHKLINE PHARMACEUTICALS LTD.

GSK India Q2 FY27: Consolidated PAT jumps 30% YoY on 21% revenue growth, beats guidance

pharmaceuticals · seasonal demand · margin expansion

ResultsQ2 FY273 minPharma & Healthcare
AMRUTANJANAMRUTANJAN HEALTH CARE LTD.-$

Amrutanjan Q2 FY27: PAT up 24% YoY to ₹17.3 Cr as margins expand, hygiene turns profitable

fmcg · otc pharma · pain relief balms

ResultsQ2 FY273 minPharma & Healthcare
ANTHEMAnthem Biosciences Ltd

Anthem Biosciences consolidated PAT +22% YoY, margins expand as revenue recovers from Q1

crdmo · margin expansion · speciality ingredients

ResultsQ2 FY273 minPharma & Healthcare
AMANTAAmanta Healthcare Ltd

Amanta Healthcare Q2 FY27: PAT up to ₹4.86 Cr, margins expand YoY as SteriPort ramps

pharmaceuticals · parenteral solutions · margin expansion

ResultsQ2 FY273 minPharma & Healthcare
JAGSNPHARMJAGSONPAL PHARMACEUTICALS LTD.

Mission 2028 on track, but Q2 organic growth lags targets

INR500 acquisition strategy · organic underperformance · hospital channel entry

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
MEDANTAGlobal Health Ltd

Medanta Q2 FY27: consolidated PAT +38% YoY (~54% adjusted), revenue +34%, margins widen

hospital services · margin expansion · revenue growth

ResultsQ2 FY273 minPharma & Healthcare
MAXINDMax India Ltd

Max India loss narrows 35% YoY to ₹22 Cr, consolidated; Senior Living turns profitable

senior living · assisted care · holding company

ResultsQ2 FY273 minPharma & Healthcare
NEULANDLABNEULAND LABORATORIES LTD.

Neuland Q2: consolidated PAT -47% YoY to ₹51.6 Cr on 13% revenue decline, margins compress

pharma cdmo · api manufacturer · margin compression

ResultsQ2 FY273 minPharma & Healthcare
CONCORDBIOConcord Biotech Ltd

Growth Holds, But Profits Lag — Execution on New Units Is the Tell

earnings · margin compression · API growth

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
CONCORDBIOConcord Biotech Ltd

Solid growth masks margin pressure; long-term drivers intact

API-led growth 30% YoY · Gross margin compression 400 bps · Immunosuppressant momentum

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
SUDEEPPHRMSudeep Pharma Ltd

Record Growth and 310bp Margin Lift — But 100bp Is Borrowed

battery-grade iron phosphate · margin expansion · specialty ingredients recovery

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
SUDEEPPHRMSudeep Pharma Ltd

Record revenue, margin upside, but specialty ingredients stumble

battery-grade iron phosphate · greenfield FDA approval · magnesium bisglycinate

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
HIKALHIKAL LTD.

Hikal Q2 FY27: consolidated loss narrows to ₹6.1 Cr YoY as revenue jumps 36%, OPM expands to 10.3%

pharmaceuticals · crop protection · margin expansion

ResultsQ2 FY273 minPharma & Healthcare
YATHARTHYatharth Hospital & Trauma Care Services Ltd

Yatharth Q2FY27: consolidated revenue +54% YoY, margin compression caps PAT at +17%

hospital chain · healthcare · margin compression

ResultsQ2 FY273 minPharma & Healthcare
EMCUREEmcure Pharmaceuticals Ltd

Emcure Q2 FY27: consolidated PAT +29% YoY to ₹325 Cr, margin expands, beats guidance

margin expansion · international growth · guidance beat

ResultsQ2 FY273 minPharma & Healthcare
ONESOURCEOnesource Specialty Pharma Ltd

37% Revenue Growth, Unchanged Guidance: The Onesource Paradox

DDC capacity ramp · semaglutide supply · line 3 delay

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
KOPRANKOPRAN LTD.

Kopran turns profitable YoY in Q2 FY27 — consol PAT ₹4.4 Cr vs loss; revenue up 79%

pharmaceuticals · api · profit turnaround

ResultsQ2 FY273 minPharma & Healthcare
ONESOURCEOnesource Specialty Pharma Ltd

Strong growth, execution on track; geopolitical headwinds offset by capacity ramp

DDC expansion · semaglutide commercialization · biologics MSA wins

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
LAURUSLABSLaurus Labs Ltd

Record quarter, but ₹3,000-Crore capex repricing shifts focus to execution

CDMO growth · capex intensity · peptide validation

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
LAURUSLABSLaurus Labs Ltd

Record Q2 growth, but capex surge and Q3 softness cloud near-term

CDMO 86% growth · peptide validation · ₹3K capex raise

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
02 Nov 2026
AKUMSAkums Drugs and Pharmaceuticals Ltd

Akums Q2 FY27: Consol PAT up 168% YoY to ₹114.6 Cr, revenue +32%, margin in guided band

cdmo growth · margin expansion · pat surge

ResultsQ2 FY273 minPharma & Healthcare
GRANULESGRANULES INDIA LTD.-$

Granules India Q2 FY27: PAT Surges 39% YoY to ₹182 Cr, Margin Just Shy of Guided Band

pharmaceuticals · generics · margin compression

ResultsQ2 FY273 minPharma & Healthcare
BPLPHARMABharat Parenterals Ltd

Innoxel Inflection, Margin Test — The Real Quarter Below the Headline

CMO inflection · margin compression · Innoxel licensing

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
BPLPHARMABharat Parenterals Ltd

Innoxel inflection tempered by near-term margin pressure

commercial inflection · CMO export · material cost inflation

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
FABTECHFabtech Technologies Ltd

Profit Surge, Revenue Stumble: The ₹50 Crore H2 Execution Test

order book · margin expansion · geopolitical headwind

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
FABTECHFabtech Technologies Ltd

Profit surge masks revenue miss; execution on H2 critical

order book · margin expansion · geopolitical headwind

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
KRSNAAKrsnaa Diagnostics Ltd

Krsnaa Diagnostics Q2 FY27: PAT growth stalls to 3% YoY as margins compress

diagnostics · margin compression · rajasthan ramp-up

ResultsQ2 FY273 minPharma & Healthcare
PGHLProcter & Gamble Health Ltd

P&G Health Q2 FY27: Standalone PAT Up 26% YoY to ₹111.5 Cr, Margins Expand, Tops Own Preview Range

pharmaceuticals · margin expansion · standalone results

ResultsQ2 FY273 minPharma & Healthcare